Skip to main content

Table 1 Patient and tumor characteristics by type of initial radiation treatment

From: Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer

Characteristics Total (%)* Patients (n) BT alone (%) EBRT alone (%) EBRT+BT (%) Others§(%)
Total 100.0 8946 (3153) 26.1 54.9 17.6 1.4
States (p < 0.0001)       
  A 22.6 2025 (502) 20.9 67.1 8.3 3.7
  B 22.7 2028 (906) 21.2 43.9 34.1 0.8
  C 6.9 618 (174) 30.4 59.1 9.9 0.6
  D 10.0 892 (586) 30.8 50.8 16.2 2.2
  E 8.7 776 (251) 25.7 53.0 21.3 0.0
  F 19.4 1739 (433) 26.7 57.4 15.9 0.0
  G 9.7 868 (301) 40.3 49.8 8.1 1.8
Age (y) (p < 0.0001)       
  20–59 14.7 1316 (499) 27.8 43.5 27.4 1.3
  60–69 37.7 3375 (1251) 29.5 49.4 20.1 1.0
  70+ 47.6 4255 (1403) 22.8 62.7 12.7 1.8
Race (p < 0.0001)       
  White, non-Hispanic 72.4 6478 (1805) 28.4 52.1 18.4 1.1
  Black, non-Hispanic 19.4 1737 (1002) 20.1 61.0 18.1 0.8
  Hispanic 5.6 497 (195) 19.7 65.4 7.0 7.9
  Asians/others 2.6 234 (151) 18.8 63.1 16.1 2.0
Marital status (p = 0.2000)       
Single 22.6 1949 (730) 24.0 58.2 16.9 0.9
  Married 77.4 6680 (2317) 27.0 53.2 18.3 1.5
Education§ (p < 0.0001)       
  Not undereducated 64.5 5751 (1787) 29.0 51.0 18.7 1.3
  Undereducated 35.5 3166 (1357) 21.0 61.7 15.6 1.7
Working class (p = 0.0075)       
  Not working class 43.7 3893 (1203) 28.2 50.5 19.8 1.5
  Working class 56.3 5025 (1941) 24.5 58.2 15.9 1.4
Urbanization (p = 0.3671)       
  Urban 48.5 4324 (1468) 26.4 54.7 17.2 1.7
  Rural 15.4 1372 (525) 23.6 59.7 15.8 0.9
  Urban-Rural mix 36.1 3221 (1151) 26.8 52.9 18.9 1.4
Poverty level (p = 0.0013)       
  Not in poverty level 81.1 7233 (2317) 27.1 53.2 18.4 1.3
  In poverty level 18.9 1685 (827) 21.7 61.9 14.4 2.0
Health insurance (p = 0.0010)       
  Not insured 1.3 111 (50) 11.8 71.2 12.3 4.7
  Public coverage 64.2 5535 (2009) 25.1 57.6 16.4 0.9
  Private coverage 30.8 2660 (857) 27.8 48.4 21.5 2.3
  Insurance, NOS 3.7 319 (131) 27.0 46.9 23.9 2.2
Piccirillo comorbidity score (p = 0.2893)       
  None 28.8 2515 (860) 29.0 51.6 17.7 1.7
  Mild 55.2 4816 (1720) 26.5 53.7 18.6 1.2
  Moderate 12.2 1060 (390) 21.2 62.1 15.6 1.1
  Severe 3.8 327 (111) 22.1 56.8 18.9 2.2
PSA (ng/ml) (p < 0.0001)       
  <10 72.1 6360 (2199) 32.7 47.9 18.3 1.1
  10–20 18.4 1620 (574) 10.2 69.8 18.0 2.0
  >20 9.5 841 (329) 5.8 78.3 13.9 2.0
TNM Clinical T stage (p < 0.0001)       
  Tx-T0 0.5 49 (18) 9.2 84.8 3.7 2.3
  T1 64.8 5793 (2064) 31.3 51.5 16.2 1.0
  T2 31.7 2832 (978) 18.2 58.9 21.0 1.9
  T3-T4 3.0 268 (92) 0.0 80.1 16.0 3.9
Gleason score (p < 0.0001)       
  2–6 56.6 5020 (1732) 37.5 46.4 14.7 1.4
  7 31.9 2836 (1020) 13.0 62.8 22.9 1.3
  8-10 11.5 1023 (375) 3.9 75.4 18.6 2.1
Recurrence risk group (p < 0.0001)       
  LR 41.2 3684 (1257) 45.2 39.9 13.8 1.1
  IR 40.1 3583 (1261) 16.1 60.0 22.5 1.4
  HR 18.8 1680 (635) 5.2 76.8 15.7 2.3
  1. BT, brachytherapy; EBRT, external beam radiation therapy; LR, low risk group; IR, intermediate risk group; HR, high/very high risk group.
  2. (*) Column percentages based on weighted number of patients.
  3. (†) Weighted number of patients, with unweighted number in parentheses.
  4. (‡) Row percentages based on weighted number of patients.
  5. (§) Included those with no RT, had RT but with unknown modality, and unknown if they had RT.
  6. (¶) p-values (Chi-square test to measure of association between RT treatment and each of socio-demographic/clinical variables).